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A B S T R A C T
Although patients with indolent B-cell lymphomas have a relatively good survival rate, conventional che-
motherapy is not curative. Disease courses are typically characterized by multiple relapses and progressively
shorter response duration with subsequent lines of therapy. There has been an explosion of innovative targeted
agents in the past years. This review discusses current knowledge on the etiology of indolent B-cell lymphomas
with respect to the role of micro-organisms, auto-immune diseases, and deregulated pathways caused by mu-
tations. In particular, knowledge on the mutational landscape of indolent B-cell lymphomas has strongly in-
creased in recent years and harbors great promise for more accurate decision making in the current wide range of
therapeutic options. Despite this promise, only in chronic lymphocytic leukemia the detection of TP53mutations
and/or del17p currently have a direct eﬀect on treatment decisions. Nevertheless, it is expected that in the near
future the role of genetic testing will increase for prediction of response to targeted treatment as well as for more
accurate prediction of prognosis in indolent B-cell lymphomas.
1. Introduction
Indolent B-cell lymphomas represent approximately one third of all
B-cell non-Hodgkin lymphomas. Although patients with these types of
lymphoma have a relatively good survival rate, morbidity and mortality
are signiﬁcant, especially considering the fact the majority of these
lymphomas is considered incurable. This review discusses recent de-
velopments in the etiology of indolent B-cell lymphomas which can
provide a rationale for prioritizing and combining novel agents.
In form and function, cells of indolent B-cell lymphomas resemble
their normal counterparts and act in close contact with and are de-
pendent on their micro-environment. This dependence on the micro-
environment is evidenced by the diﬃculty to culture indolent B-cell
lymphoma cells which indicates that these cells cannot proliferate au-
tonomously but require stimulatory signals. Examples of signals that
can stimulate the development of B-cell lymphoma include long-
standing inﬂammatory conditions in the context of infection or auto-
immune disease. Another line of evidence for the role of antigenic sti-
mulation of lymphomas comes from the fact that in multiple types of B-
cell lymphoma, stereotyped B-cell receptors have been shown,
indicating that speciﬁc antigens are implicated in lymphomagenesis.
The ﬁrst part of this review is concerned with these processes driving
the development of B-cell lymphomas.
A second issue is: what makes neoplastic B-cells diﬀerent from
normal B-cells? Which genetic events are present? It is already known
for a long time that the early genetic alterations like the t(14;18) in
follicular lymphoma are actually a common occurrence in healthy in-
dividuals and thus not suﬃcient to make a lymphocyte malignant. The
genetic revolution is rapidly changing our understanding of B-cell
lymphomas and in the second part of this review, the pathways and
mutations involved in B-cell lymphomagenesis and the drugs that target
them are discussed.
2. Micro-organisms
Multiple diﬀerent species of bacteria have been implicated in the
development of extranodal marginal zone lymphoma of mucosa-asso-
ciated lymphoid tissues (EMZL) with Helicobacter pylori being the best
studied and most convincing example (Table 1). H. pylori can be de-
tected in up to 92% of EMZL of the stomach and eradication of the
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bacterium by antibiotic treatment results in complete and long-lasting
remission of lymphoma in three quarters of patients with early-stage
disease [1–5]. In EMZL of the stomach but also of the ocular adnexa
(discussed below), the micro-organisms involved do not stimulate the
neoplastic B-cells directly, but rather cause an inﬂammatory milieu
with induction of a Th1 immune response with inﬂux of CD4 positive T-
cells which stimulate B-cell proliferation through CD40-CD40L inter-
action. At the same time, the cytotoxic T-cell response is impaired [6].
These factors lead to the outgrowth of autoreactive B-cells which can
progress to lymphoma after the acquisition of mutations. With respect
to gastric EMZL, most regress after removing the inﬂammatory stimulus
by eradication of H. pylori, but some gastric EMZLs have become H.
pylori independent. Factors associated with the lack of a response to H.
pylori eradication include a higher disease stage and the presence of
speciﬁc translocations involving the BIRC3, MALT1, or BCL10 gene
[7–9]. In both instances, it is suspected that the lymphoma cells have
already become independent of the antigenic stimulus. However, even
in diﬀuse large B-cell lymphoma (DLBCL) of the stomach, H. pylori
eradication has been reported to result in long-term remission in up to
two-thirds of patients, indicating that high-grade lymphomas may also
be antigen-dependent [10,11].
A role for Chlamydophila psittaci has been suggested in the patho-
genesis of ocular adnexal EMZL (OAMZL), following from the ob-
servation that it can be detected in up to 80% of OAMZL [12,13] and
that antibiotic treatment results in remission in a subset of patients
[13]. However, the presence of C. psittaci in OAMZL varies greatly be-
tween studies, which can at least partially be explained by geographical
diﬀerences [12–22]. In addition, diﬀerences in detection protocols for
C. psittaci could also be part of the explanation as studies from similar
regions (e.g. Italy, the Netherlands, United States) have showed strong
diﬀerences in C. psittaci incidence in OAMZL.
With respect to treatment, most studies showed partial or complete
responses in approximately 45% of patients with OAMZL treated with
doxycycline antibiotics [23]. However, only two of three studies
showed improved response in C. psittaci-positive cases. In those two
studies, the response rates were 66% vs. 50% and 64% vs. 38% for C.
psittaci positive vs. negative patients [24,25]. These results suggest that
although C. psittaci may have a role in the development of OAMZL and
is amenable to antibiotic treatment, other (Doxycycline sensitive)
bacteria or direct anti-tumor eﬀects of the antibiotics used may also
have a role in eradication of the lymphoma. Conversely, detection
methods may be insuﬃcient. In conclusion, the role of antibiotic
treatment in OAMZL is speculative at best and requires additional
study.
In the rare cutaneous EMZL, Borrelia burgdorferi has been suggested
as a causative agent, with varying frequencies depending on the region
where the studies were performed. In endemic areas, up to 40% of
cutaneous EMZL showed evidence of Borrelia infection [26–28]. An-
ecdotal reports have shown tumor response to antibiotic therapy
against Borrelia [23].
In immunoproliferative small intestinal disease (IPSID),
Campylobacter jejuni has been reported as a possible causative micro-
organism [29,30]. However, the evidence for this association is limited
to anecdotal reports and no clinical studies have been performed. In
pulmonary EMZL, Achromobacter xylosidans has been detected with
increased frequency in lymphomas in comparison to controls, but these
results are limited to a single study and have not been validated clini-
cally [31]. Finally, regarding the role of bacteria in the pathogenesis of
indolent lymphoma, epidemiological studies have shown an association
between an increased risk of CLL and a history of pneumonia [32]. In
primary intraocular B-cell lymphoma, the presence of Toxoplasma gondii
has been reported [33].
Co-occurrence of Hepatitis C virus (HCV) infection and lymphoma
has been reported in multiple types of non-Hodgkin lymphoma, in-
cluding indolent B-cell lymphomas. Within the group of indolent B-cell
lymphomas, lymphoplasmacytic lymphoma and marginal zone lym-
phoma (MZL, particularly splenic MZL and non-gastric MALT lym-
phoma) are most often associated with HCV infection. However, the
association between B-cell lymphoma and HCV has varied signiﬁcantly
between studies, with stronger associations in those areas with a higher
HCV prevalence. In systematic reviews, 13%–18% of B-cell lymphomas
were HCV-associated [34–36]. In addition to epidemiological data, re-
gression of lymphoma after eradication of HCV with antiviral therapy
provides further evidence for a role of HCV in B-cell lymphoma de-
velopment. Response of lymphoma to antiviral treatment has been re-
corded in extranodal, splenic, and nodal MZL and in smaller numbers of
lymphoplasmacytic lymphoma (LPL) and follicular lymphoma (FL)
[37–44]. The studies reported thus far with a total number of almost
200 patients, reported an overall response rate of 62–100% and com-
plete response rate of 50–89% [45]. Accordingly, antiviral treatment
Table 1
Micro-organisms in indolent B-cell lymphomas.
Micro-organism Related lymphoma Summary of association
Helicobacter pylori MALT lymphoma of the stomach Strong evidence for association:
• H. pylori present in up to 92% of MALT lymphomas.• Eradication results in long-term remission in three quarters of patients with early-stage
disease.
• Translocations in BIRC3, MALT1 and/or BCL10 predict resistance to eradication treatment.
Chlamydophila psittaci Ocular adnexal MALT lymphoma Some evidence for association
• C. psittaci present in subset of OAMZL, varying between regions and with detection
methods.
• Response to antibiotic treatment in a subset of patients with C. psittaci positive lymphoma,
but also in patients with C. psittaci negative lymphoma.
Borrelia burgdorferi Cutaneous MALT lymphoma Some evidence for association
• B. burgdorferi DNA present in a subset of cutaneous MALT lymphoma.• Anecdotal reports of lymphoma response to antibiotic treatment.
Campylobacter jejuni Immunoproliferative small intestinal disease (IPSID) Anecdotal reports of association and lymphoma response to antibiotics.
Achromobacter xylosidans Pulmonary MALT lymphoma A. xylosidans DNA detected more frequently in pulmonary MALT lymphoma than control
tissue in a single study.
Epstein Barr virus No speciﬁc type Only very rarely reported in low-grade B-cell lymphoma
Hepatitis C virus MALT lymphoma (particularly non-gastric), SMZL,
NMZL, LPL, FL
Strong evidence for association
• Co-occurrence of HCV infection and lymphoma, with strong geographical variation.• Regression of lymphoma with antiviral therapy in 62–100% of patients.
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can be considered as ﬁrst-line treatment in patients with indolent B-cell
lymphoma in whom immediate antilymphoma therapy is not necessary
due to limited stage of disease or low tumor burden. Novel agents
against HCV (e.g. sofosbuvir, simeprevir) are also promising in the
setting of lymphoma arising in patients with HCV. In two recent case
reports, regression of SMZL was reported after interferon free HCV
treatment [46,47], but formal studies have not been reported yet. The
mechanisms by which HCV induces lymphoma are not well understood,
but possibilities include chronic antigenic stimulation and/or a direct
oncogenic eﬀect of the virus [36].
3. Stereotyped B-cell receptors
Although micro-organisms have been implicated in the develop-
ment of B-cell lymphoma, the neoplastic B-cells usually do not have
BCRs that recognize antigens belonging to these micro-organisms.
Therefore, infections appear to contribute mainly by forming a pro-
inﬂammatory environment rather than directly stimulating the neo-
plastic cells. The question then arise to what extent antigen stimulation
is necessary for B-cell lymphoma development and which antigens are
involved. With respect to the ﬁrst part of this question, several lines of
evidence argue for a role of antigens in lymphomagenesis.
First, the BCR is retained in the majority of B-cell lymphomas and
most lymphoma cells cannot survive autonomously ex vivo. This sug-
gests a dependence on the micro-environment and on signaling through
the BCR [48]. Second, studies into the structure of the B-cell receptor
have revealed stereotyped B-cell receptors in diﬀerent types of B-cell
lymphoma.
In chronic lymphocytic leukemia (CLL), multiple subsets with spe-
ciﬁc stereotyped receptors have been recognized, with approximately
one third of CLLs having a stereotypic BCR [49]. Part of these stereo-
types are associated with a speciﬁc clinical presentation or prognosis. In
splenic MZL, about one third of lymphomas express the same im-
munoglobulin heavy chain variable gene. The fact that the BCRs in
diﬀerent lymphomas show a similar IGH structure suggests selection of
tumor cells by speciﬁc antigens or superantigens [50].
If B-cell lymphomas are dependent on antigens for their survival,
then which antigens are responsible? In both SMZL and CLL, it has been
shown that the BCRs of the neoplastic cells are often reactive to self-
antigens, including antigens which are expressed during cell death
[51–55]. In addition, reactivity to viral bacterial and fungal antigens
has also been suggested, but the bacteria implicated are diﬀerent from
those previously discussed in the context of MALT lymphoma. In CLL,
the neoplastic cells can express BCRs that react with epitopes on
common bacteria [56]. Also in CLL, an association between usage of the
immunoglobulin heavy chain variable 4-34 (IGH4-34) gene and acti-
vation of EBV and CMV, suggesting that viral antigens could facilitate
clonal expansion and neoplastic transformation [57].
4. Auto-immune diseases
Auto-immune diseases are associated with an increased risk of
lymphoma [58]. In particular Sjögren's syndrome and systemic lupus
erythematosus were associated with an increased risk of lymphoma in a
large pooled analysis [59]. With respect to indolent B-cell lymphomas
in the context of auto-immune disease, development of MZL in Sjögren's
syndrome is the most striking example. Patients with Sjögren's syn-
drome have a 7-fold increased risk of non-Hodgkin lymphoma and a
1000-fold increased risk of MZL of the parotid gland [59]. Clinical and
laboratory feature that predict lymphoma development include per-
manent swelling of the salivary glands, oral and ocular symptoms,
vasculitis, lymphadenopathy, purpura, cryoglobulinemia, lympho-
penia, low C4, M-protein and germinal center-like structures in the
salivary gland.
With respect to the pathophysiology of lymphoma development in
Sjögren's syndrome, it has been suggested that the B-cell clone often has
a B-cell receptor with rheumatoid factor (RF) activity, being directed
against the Fc portion of IgG [60–63]. The hypothesis is then that
polyclonal B-cells which are activated in the auto-immune in-
ﬂammatory environment acquire additional mutations and eventually
grow out to become a B-cell lymphoma [62].
5. Preneoplastic conditions
Much has been learned about the pathogenesis of indolent lym-
phomas from precursor lesions, which include precursors of FL and
monoclonal B-cell lymphocytosis (MBL).
Deregulation of BCL2 by the t(14;18) translocation is the hallmark
genetic lesion of FL. However, this translocation in itself is insuﬃcient
for neoplastic transformation. This is well illustrated by studies into FL
and its precursors. With highly sensitive techniques, cells harboring the
t(14;18) translocation can be detected in over half of the healthy adult
population, of which only a very small minority will develop FL
[64,65]. These cells carrying the t(14;18) are antigen experienced and it
is hypothesized that multiple re-entries in the germinal center with
aberrant somatic hypermutation induce mutations, thereby con-
tributing to oncogenesis. In situ follicular neoplasia (ISFN, also termed
follicular lymphoma in situ) is a coincidentally detected phenomenon in
lymphoid tissue in which BCL2 and CD10 positive cells colonize
germinal centers without architectural distortion. The cells in these
follicles have a t(14;18) translocation, but also carry additional
genomic alterations [66], suggesting that ISFN could represent a step in
between the t(14;18) positive cells detected in healthy individuals and
overt FL. Only approximately 5% of individuals with ISFN have de-
veloped FL in small studies [67].
MBL is the presence of a monoclonal or oligoclonal B-cell expansion
with a B-cell count of< 5 × 109 B-cells/L in the absence of symptoms
of an overt lymphoproliferative disease. Most cases of MBL (approxi-
mately 75%) have an immunophenotype resembling CLL, but other
phenotypes are also encountered. Blood samples collected before a di-
agnosis of CLL consistently show a monoclonal B-cell population, in-
dicating that CLL is preceded by MBL [68]. However, the large majority
of MBLs do not progress to CLL. MBL with a low number of clonal B-
cells in the peripheral blood (< 0.5 × 109/L), termed ‘low count’ MBL,
virtually never progress to CLL whereas ‘high count’ MBL progresses to
CLL at a rate of 1–2% per year and requires follow-up [69,70]. With
respect to the immunogenetic proﬁle, low-count MBL is diﬀerent from
CLL with more frequently mutated IGHV genes and a very low pre-
valence of BCR stereotypy in low-count MBL, whereas high-count MBL
resembles CLL with respect to IGHV mutation status and BCR stereo-
typy [71]. On the contrary, cytogenetic aberrations found in CLL can
also be found in low-count MBL, indicating that these lesions are not
necessarily associated with progression [72]. High count MBL and low-
stage CLL show similar mutational patterns, further indicating that
these conditions are part of the same spectrum [73]. Low-count MBL
appears to be a diﬀerent entity which might be related to aging [71].
6. Deregulated pathways
Recent large sequencing eﬀorts in indolent B-cell lymphomas have
substantially increased our knowledge on the molecular pathways that
are deregulated in these lymphomas. With the concurrent development
of drugs that target these speciﬁc pathways, the role of targeted treat-
ment for indolent B-cell lymphoma is likely to increase (Fig. 1). Al-
though some indolent B-cell lymphomas are characterized by highly
recurrent mutations, most lymphoma subtypes show a low number of
genes with a moderate mutation frequency followed by a long tail of
genes that are mutated in a low number of cases. The pathways that are
most frequently aﬀected are discussed below and summarized in
Table 2.
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6.1. DNA damage response and apoptosis (TP53, BCL2, and ATM)
6.1.1. TP53
TP53 is one of the most extensively studied tumor suppressor genes
and is well known for its association with a poor prognosis and re-
fractoriness to conventional chemotherapy in CLL. In fact, TP53 mu-
tations and del17p are the only mutations that currently have a direct
impact on patient care, with a preferred treatment with novel inhibitors
(ibrutinib as single agent or idelalisib combined with anti CD20 treat-
ment) in patients with TP53 mutated CLL with a treatment indication
[74,75]. The current standard method of TP53 mutation detection is
Sanger sequencing and a for next-generation sequencing a cut-oﬀ of
mutations present in> 10% allelic fraction is recommended by the
European Research Initiative on CLL (www.ericll.org). However, small
TP53 mutated subclones are also associated with a worse prognosis and
become predominant under conventional treatment, ultimately causing
treatment refractoriness [76]. Therefore, low frequency TP53 muta-
tions in CLL, which can be detected by sensitive next generation se-
quencing techniques, may be of clinical relevance, and should be re-
ported with caution until validation of their prognostic and predictive
impact in a larger patient group. Whether treatment with for instance
BTK inhibitors will provide similar beneﬁt as it does in patients
with> 10% allelic fraction remains to be elucidated. In addition to
CLL, an association between TP53 mutations and a worse prognosis has
also been shown for FL and MZL [77,78].
6.1.2. BCL2
BCL2 is an anti-apoptotic protein which was initially discovered as
the deregulated gene involved in the t(14;18) translocation in FL [79].
In the physiological situation, it is part of the balance between pro-
apoptotic and anti-apoptotic proteins in the intrinsic/mitochondrial
apoptotic pathway. In the large majority of FLs, overexpression of BCL2
can be explained by the t(14;18) translocation which puts BCL2 under
the control of the IGH enhancer. More rarely, translocations between
BCL2 and the immunoglobulin light chain loci are encountered. How-
ever, many small B-cell lymphomas other than FL express BCL2 without
evidence of a BCL2 rearrangement. This can be explained by other
mechanisms of BCL2 expression, especially physiological expression,
but also BCL2 ampliﬁcation, hypomethylation, or deletion of micro-
RNAs that downregulate BCL2 [80–83].
BCL2 is a target for BCL2 inhibitors venetoclax and navitoclax
which are currently under investigation for their eﬀectiveness is mul-
tiple lymphoma subtypes. In Europe, the European Medicines Agency
(EMA) has approved venetoclax for the treatment of CLL with 17p
deletion or TP53 mutation in adult patients who are unsuitable for or
have failed a B-cell receptor pathway inhibitor and also for the treat-
ment of CLL in the absence of 17p deletion or TP53 mutation in adult
patients who have failed both chemoimmunotherapy and a B-cell re-
ceptor pathway inhibitor. In the United States, venetoclax has been
approved by the Food and Drug Administration (FDA) for treatment of
patients with CLL with a 17p deletion who have received at least one
prior therapy.
Fig. 1. Deregulated pathways in B-cell lymphoma with targeted treatments.
Table 2
Mutated genes and their relevance in indolent B-cell lymphomas.
Lymphoma subtype Mutated gene Relevance of mutation present
Chronic lymphocytic leukemia/small lymphocytic
lymphoma
TP53 Associated with worse prognosis.
Treatment with novel inhibitors (ibrutinib, idelalisib)
NOTCH1 Associated with worse prognosis and rituximab resistance
BIRC3 Associated with worse prognosis
SF3B1 Associated with worse prognosis
ATM Associated with worse prognosis
Follicular lymphoma BCL2 Translocation speciﬁc for FL
Mutations associated with disease progression
MLL2, EZH2, EP300, MEF2B Histone-modifying genes frequently aﬀected in FL
CARD11, CD79A/B, PRKCB NF-kappaB activating mutations, present in one third of follicular lymphomas.
TP53 Associated with worse prognosis
TNFRSF14 Aﬀected by loss of 1p36 or mutations
MALT lymphoma BIRC3, MALT1, BCL10 Involved in translocations activating NF-kappaB and predicting resistance to H. pylori
eradication in gastric MALT lymphoma
TNFAIP3 Frequently mutated NF-kappaB inhibitor
Splenic marginal zone lymphoma NOTCH2 Mutated in 10–25% of SMZLs, master regulator of marginal zone diﬀerentiation
KLF2 Mutated in 20–40% of SMZLs, causing NF-kappaB activation. Associated with short
time to ﬁrst treatment.
TNFAIP3, MYD88, TRAF3
CARD11
NF-kappaB activating mutations
TP53 Associated with short overall survival
Lymphoplasmacytic lymphoma MYD88 Mutated in> 90% of LPLs. In LPL (but not DLBCL) associated with response to
ibrutinib
CXCR4 Mutations in 30% of LPLs, associated with ibrutinib resistance
Nodal marginal zone lymphoma Recurrent mutations reported in MLL2, PTPRD, NOTCH2, KLF2, TNFAIP3 and CD79B
M. van den Brand et al. Blood Reviews 31 (2017) 426–435
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6.1.3. ATM
Inactivation of ATM (located at 11q22) by deletion and/or mutation
is a frequent event in CLL with deletions of 11q22-23 in< 10% in
newly diagnosed CLLs, rising to approximately 20% at the time of ﬁrst
treatment. Mutations in ATM are present in 10–15% of CLL at ﬁrst di-
agnosis and approximately 15% at the time of ﬁrst treatment [75].
Together, genetic lesions are present in ATM in CLL in approximately
20% at the time of diagnosis and approximately 35% at the time of ﬁrst
treatment [84]. The ATM gene encode for a serine/threonine kinase
which prevents cell cycle progression and activated DNA repair me-
chanisms in the event of chromosomal double strand breaks.
6.2. B-cell receptor/toll-like receptor/NF-kappaB signaling
Signals from multiple receptors converge on the NF-kappaB
pathway (Fig. 2). Canonical and non-canonical NF-kappaB signaling are
distinguished. Canonical NF-kappaB signaling starts from the B-cell
receptor, T-cell receptor, Toll-like receptors (TLR), interleukin-1 re-
ceptor (IL1R) or tumor necrosis factor receptor (TNFR). Through mul-
tiple steps which include the proteins CD79A/B, SYK, BTK, CARD11,
BCL10, TRAF6 and MYD88, the inhibitor of kappa-B kinase (IKK)
complex is activated. Activation of this complex results in the removal
of inhibitory elements from NF-kappaB proteins, allowing these pro-
teins to enter the nucleus to regulate transcription. NF-kappaB signaling
is negatively regulated by deubiquitinases which include CYLD (cylin-
dromatosis) and TNFAIP3 (also known as A20).
The non-canonical pathway is activated by signaling from the
lymphotoxin B receptor, B-cell activating factor receptor (BAFFR), and
CD40. This activates NF-kappaB inducible kinase (NIK, also known as
MAP3K14) and CHUK, also eventually resulting in translocation of NF-
kappaB proteins to the nucleus.
Deregulation of pathways that converge on NF-kappaB is frequently
observed in lymphomas. In indolent B-cell lymphomas, extranodal
marginal zone lymphoma is the most prominent example with frequent
translocations involving MALT1, BIRC3 (also known as API2), and
BCL10 [85–89]. In addition, extranodal MZLs harbor frequent
mutations in genes involved in NF-kappaB signaling including TNFAIP3
[90]. Also in SMZL and NMZL, mutations in genes involved in NF-
kappaB signaling are frequent and most notably include TNFAIP3,
IKBKB, CARD11, BIRC3 and rarely MYD88 [78,91–95]. MYD88 muta-
tions are present in the large majority of LPLs, which is very helpful for
diagnosis [93,96–98]. Almost all mutations aﬀect the TIR domain with
NF-kappaB activation as a result. In a subset of CLL/SLL, mutations in
BIRC3 are detected with enrichment in ﬂudarabine-refractory cases
[99]. In patients with TP53mutated CLL, additional mutations in BIRC3
are associated with an even worse prognosis. MYD88 mutations have
been found in a small subset of CLL/SLLs, mainly in cases with mutated
IGHV [98].
In FL, mutations in genes involved in BCR/NF-kappaB signaling are
relatively frequent with mutations in CARD11, TNFAIP3, CD79A/B,
and/or PRKCB being present in a third of FLs [100]. Interestingly,
mutations in NF-kappaB genes were gained at transformation [100].
Mutations in TNFRSF14 are also frequently present in FL, being re-
ported in approximately one third of cases [100–102]. TNFRSF14 is a
putative tumor suppressor which can signal through the NF-kappaB
pathway after binding of one of its ligands which include LIGHT, BTLA
or CD160 [103]. However, as loss-of-function mutations in TNFRSF14
are observed in FL, these mutations would cause a decrease rather than
an increase of NF-kappaB activation. The tumor suppressor eﬀect of
TNFRSF14 can be explained by the fact that in the unmutated situation,
triggering of TNFRSF14 by its ligand LIGHT increases the sensitivity to
FAS-induced apoptosis. Disruption of TNFRSF14 would then make cells
less sensitive to apoptosis, contributing to lymphomagenesis [104,105].
6.2.1. B-cell receptor signaling inhibitors
Multiple drugs have recently become available that targets signaling
to NF-kappaB (Fig. 2). Ibrutinib blocks this signaling by binding cova-
lently to BTK at cysteine 481, thereby preventing phosphorylation and
blocking of downstream signaling [106,107]. Ibrutinib has been ap-
proved by the FDA for treatment of patients with CLL, recurrent MCL,
Waldenström macroglobulinemia and recently also marginal zone
lymphoma. In Europe, its use has been approved for patients with CLL,
Fig. 2. Overview of BCR/TLR/NF-kappaB signaling with tar-
geted treatments. Non-canonical signaling via LTR/CD40/
BAFFR is indicated on the right. Canonical NF-kappaB signaling
is indicated on the left. Activation of BCR signaling induces NF-
kappaB activation via SYK, BTK, and PKCB. In addition, BCR
signaling activates the PI3K pathway. IL1R and TLR signaling
also induce NF-kappaB activation. In lymphoplasmacytic lym-
phoma, mutated MYD88 causes BTK activation. Ibrutinib, SYK
inhibitors and idelalisib/duvelisib target diﬀerent steps in these
signaling cascades. Proteasome inhibitors decrease breakdown
of inhibitors of NF-kappaB, causing decreased NF-kappaB sig-
naling.
Abbreviations: BAFFR: B-cell activating factor receptor; BCR: B-
cell receptor; IL1R: interleukin-1 receptor; LTR: lymphotoxin B
receptor; NF-kappaB: nuclear factor kappa B; TLR: Toll-like re-
ceptor.
M. van den Brand et al. Blood Reviews 31 (2017) 426–435
430
recurrent MCL, and Waldenström macroglobulinemia. In addition, ef-
ﬁcacy of ibrutinib has been shown in DLBCL, mainly in the activated B-
cell-like (ABC) subtype [108,109]. However, not all patients show a
response to ibrutinib and both primary and secondary mechanisms of
resistance have been identiﬁed [108]. Primary resistance mechanisms
have been mainly studied in MCL and DLBCL and include mutations
that cause activation the non-canonical NF-kappaB pathway (e.g.
TRAF2 and TRAF3), mutations that activate the canonical NF-kappaB
pathway independent of BTK (MYD88 mutations) [109,110]. In lym-
phoplasmacytic lymphoma (LPL), MYD88 mutations predict response
rather than resistance to ibrutinib, which is in line with experiments
showing BTK phosphorylation after mutant MYD88 overexpression in
LPL [111]. MYD88 L265P mutations are present in the large majority
(> 90%) of lymphoplasmacytic lymphomas [96,112,113], and patients
with MYD88 mutated LPL show a major response in 91% versus only
29% in patients with MYD88 wildtype LPL [114]. Mutations in CXCR4
are associated with a decreased response to ibrutinib in LPL with a
major response rate of 91% vs. 62% for patients with LPL without and
with CXCR4 mutations. This might be caused by activation of AKT
signaling by CXCR4 mutations in which the mechanism might be si-
milar to that in MCL as discussed above [115,116]. CXCR4 is a G-
protein coupled chemokine receptor with a role in lymphocyte homing
and migration. CXCR4 mutations of WHIM-like type are present in 30%
of LPLs. WHIM-like describes the presence of nonsense and frameshift
mutations that are also present in the germline of patients with Warts,
Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syn-
drome.
In CLL, an unmutated BCR appears to be related to a better response
to ibrutinib, which could be due to a larger dependence on BCR sig-
naling in BCR unmutated CLL [108,117]. Secondary resistance to
ibrutinib occurs as well. In both CLL and MCL, C481S mutations in BTK
have been detected after ibrutinib therapy which were not present
before therapy [118,119]. This mutation is located at the active site of
BTK and causes a strong decrease in the aﬃnity for ibrutinib for BTK. In
addition, mutations in PLCG2 have been detected after treatment with
ibrutinib [119]. These are gain-of-function mutations which activate
BCR signaling downstream of BTK [120].
Other novel drugs in targeting B-cell receptor signaling are directed
against PI3K or SYK. Idelalisib and duvelisib are inhibitors of PI3K that
target speciﬁc isoforms of the p110 subunit of PI3K. Idelalisib targets
the delta isoform and duvelisib targets both the delta and gamma iso-
form. Idelalisib has been shown to be eﬀective in patients with relapsed
CLL [121] and indolent non-Hodgkin lymphoma (NHL), including FL,
MZL, and LPL [122,123]. In MCL, idelalisib was also eﬀective but the
majority of patients showed only a short response duration [124]. Re-
sistance mechanisms for idelalisib have not been studied as well as for
ibrutinib, but higher expression of other PI3K isoforms has been sug-
gested as a mechanism from in vitro studies [125]. In addition, acti-
vation of other oncogenic pathways such as MYC has been hypothesized
as a mechanism for idelalisib resistance [126]. Idelalisib has been ap-
proved by the FDA for treatment of patients with relapsed CLL in
combination with rituximab and for patients with relapsed FL and SLL.
In Europe, idelalisib is authorized in combination with rituximab for
use in patients with refractory FL and patients with refractory CLL or
CLL with 17p deletion and/or TP53 mutation in patients who are too
frail for standard chemotherapy.
6.2.2. Proteasome inhibitors
Inhibition of the proteasome in hematological as well as solid tu-
mors induces a wide range of eﬀects including anti-proliferative and
pro-apoptotic eﬀects in vitro [127]. Although the ubiquitin-proteasome
system also has key functions in normal cells, proteasome activity has
been shown to be higher in hematological malignancies, forming a basis
for in vivo use of proteasome inhibitors in these tumors [128,129]. In
addition to NF-kappaB pathway inhibition, proteasome inhibitors cause
inhibition of ERK signaling, upregulation of pro-apoptotic proteins,
downregulation of anti-apoptotic proteins, anti-angiogenic eﬀects, in-
hibition of DNA repair, disruption of tumor-microenvironment inter-
actions, and stabilization of p21, p27, and p53 [130]. Proteasome in-
hibitors are currently registered for multiple myeloma (bortezomib,
carﬁlzomib) and MCL (bortezomib). In addition, inhibitors of the im-
munoproteasome are under development. Immunoproteasomes are
predominantly present in hematopoietic cells and immunoproteasome
inhibition is therefore a potentially more targeted method of protea-
some inhibition [127]. Furthermore, compounds that inhibit compo-
nents of the ubiquitin-proteasome system other than the proteasome are
being developed [127].
6.3. BCL6
The BCL6 gene located on chromosome 3q27 encodes a sequence
speciﬁc repressor of transcription that serves as a master regulator of
the germinal center phenotype. It is essential for formation of germinal
centers, and mice lacking BCL6 are unable to form germinal centers
[131]. In the normal germinal center, high proliferation occurs together
with genomic instability due to somatic hypermutation. In this context,
BCL6 functions as a repressor of normal control mechanisms of the cell
cycle, DNA damage response, and cell death. Although this action is
necessary to generate B-cells with high-aﬃnity antibodies, it is also
dangerous because it may lead to deregulated growth and therefore
BCL6 expression is tightly regulated in the normal situation. However,
deregulated BCL6 expression is a common event in B-cell lymphomas
and multiple mechanisms can cause this. Translocations which put
BCL6 under the control of a strong promoter such as IGH are a frequent
event in DLBCL and are also present in a subset of FLs [132–134]. Al-
ternative mechanisms include mutations in binding sites for repressive
transcription factors [135], mutations in MEF2B which is a transcrip-
tional activator of BCL6 [136], hypermethylation of intron 1 preventing
silencing by CTCF [137], and posttranscriptional regulation [131].
6.3.1. BCL6 inhibitors
Studies into BCL6 inhibitors are currently limited to in vitro and
mice studies. These studies show a strong response of tumors to BCL6
inhibition in vitro and in vivo, but oncogene addiction to BCL2 was
observed in response to BCL6 inhibition, indicating that BCL6 inhibitors
could be particularly useful in combination with BCL2 inhibitors
[138–140]. In addition to drugs speciﬁcally targeting BCL6, histone
deacetylase (HDAC) inhibitors also counteract the eﬀects of BCL6
[141].
6.4. NOTCH signaling
Mammals possess 4 diﬀerent NOTCH genes that encode for re-
ceptors involved in self-renewal and diﬀerentiation [142]. Upon
binding of their ligands, a cleavage step causes release of the in-
tracellular part of NOTCH which then translocates to the nucleus where
it forms a protein complex with other proteins including MAML and
histone acetyltransferases (e.g. EP300) [143]. This complex then sti-
mulates transcription of a number of genes, resulting in increased ex-
pression of MYC and activation of the PI3K/AKT, mTOR, and NF-
kappaB pathway [142–144]. NOTCH1 is essential for normal T-cell
development, but is also frequently mutated in T-cell acute lympho-
blastic leukemia [145]. These mutations occur in the heterodimeriza-
tion and/or PEST domain. The PEST domain is the target for the FBXW7
ubiquitin protein ligase which targets NOTCH1 for the proteasome.
Mutations in the PEST domain prevent ubiquitination and down-
regulation of NOTCH. Mutations in the heterodimerization domain
cause enhanced cleavage of membranous NOTCH [145]. In indolent B-
cell lymphomas, NOTCH1 mutations have been reported in a subset of
CLL, SMZL, and FL [93,98,146–148]. In CLL, NOTCH1 mutations are
detected in approximately 15% with a higher frequency in CLL with
unmutated IGHV and/or trisomy 12 [75]. NOTCH1 mutations in CLL
M. van den Brand et al. Blood Reviews 31 (2017) 426–435
431
are associated with a worse prognosis and a lack of response to ritux-
imab treatment [149]. NOTCH2 is the master regulator of marginal
zone diﬀerentiation and NOTCH2 mutations are detected in up to one
quarter of SMZLs with an association with short time to ﬁrst treatment
[78,93,95,147].
6.5. Epigenetic deregulation
Recent large-scale sequencing eﬀorts have identiﬁed frequent mu-
tations in genes involved in chromatin modulation in B-cell lymphomas
[100,150–152]. These have been most extensively studied in DLBCL
and FL in which mutations in MLL2 (KMT2D), CREBBP, EP300, and
EZH2 were most frequently observed. Most of these mutations are loss-
of-function mutations, except for mutations in EZH2 which are gain-of-
function. These mutations result in epigenetic silencing of speciﬁc ge-
netic loci involved in cell cycle progression and regulation of the
germinal center reaction, contributing to lymphomagenesis [153].
6.5.1. Epigenetic therapy
In hemato-oncology, HDAC inhibitors are mainly used for the
treatment of patients with T-cell lymphoma, but limited studies have
also been performed in B-cell lymphomas with variable results
[154,155]. In addition to HDAC inhibitors, EZH2 inhibitors are under
investigation for treatment of non-Hodgkin lymphomas [156].
6.6. Mitogen activated protein kinase (MAPK) signaling
In hairy cell leukemia, the BRAF V600E mutation has been identi-
ﬁed by next-generation sequencing as a disease-deﬁning genetic event
[157]. BRAF is downstream from KRAS and upstream from MEK and
ERK in the MAPK pathway. The BRAF V600E mutation causes con-
stitutive activation of BRAF, resulting in cell survival [143]. For pa-
tients with relapsed or refractor hairy cell leukemia, the oral BRAF
inhibitor vemurafenib is an eﬀective treatment option [158–160].
7. Prediction of eﬀective targeted treatment
With the increase of novel targeted treatments, the pressing ques-
tion is which patient should receive which treatment. To select patients
for treatment, the diagnosis still forms a starting point to select patients,
but reﬁnements are already being added. It is expected that the use of
molecular diagnostics for treatment prediction will increase sig-
niﬁcantly as more and more mechanisms for resistance and sensitivity
become known. It can also be expected that complexity will increase as
more molecular events relevant for prediction of therapy response will
be detected and more drugs developed. This also means that large
clinical trials will become more diﬃcult as each patient will have a
diﬀerent lymphoma with a diﬀerent genetic background and novel
approaches to clinical studies should be introduced.
With respect to mutation detection, many laboratories are now
setting up panels for next-generation sequencing in lymphomas.
Recently, the European Expert Group on NGS-based Diagnostics in
Lymphomas (EGNL) summarized the current state-of-the-art in NGS for
lymphomas and is now performing validation of a panel of 30 recur-
rently mutated genes [74].
Another question that needs to be answered in the near future is
what diagnostic modalities will be required for therapy prediction.
Immunohistochemistry and NGS are important techniques in this re-
spect, but a mutation or changed protein expression is no guarantee for
a therapy response. Mutations in non-coding regions, epigenetic al-
terations, and the micro-environment could all have an impact on the
response to a particular treatment. In line with this, it will be necessary
in the future to integrate the features of a lymphoma and the en-
vironment on diﬀerent levels (i.e. genome, epigenome, proteome,
micro-environment) to provide the most accurate prediction of therapy
response.
8. Conclusion
Developments are following each other rapidly in the area of tar-
geted treatment of indolent lymphoma and the (epi)genetic lesions in-
volved. The challenge will be to determine which patient will beneﬁt
most from a given treatment at diﬀerent time points of disease. It is
expected that extensive genetic testing for prediction of treatment re-
sponse at diagnosis, during follow-up and at relapse will be adopted in
clinical practice soon, but for now only TP53 mutations and del17p in
CLL have a direct eﬀect on treatment decisions. The long tail of dif-
ferent mutations in many types of lymphoma and the increasing
number of drugs will require large studies to assess the impact of these
mutations on prognosis and treatment response. This challenge is be-
coming even greater with the ever increasing knowledge from multiple
sources (i.e. genome/epigenome, proteome, tumor micro-environment,
clinical features). Tumor heterogeneity and natural and chemotherapy
induced clonal evolution further increase complexity and will require
sequential analyses to optimize and adapt therapy. Particularly in in-
dolent B-cell lymphomas which are for the largest part incurable, de-
cision making based on (epi)genetic proﬁling will be important.
Practice points
• Speciﬁc bacterial infections predispose to extranodal marginal zone
lymphoma and are amenable to antibiotic treatment. However, the
evidence is only conclusive for treatment of Helicobacter pylori in
marginal zone lymphoma of the stomach.
• The mutational landscape of indolent B-cell lymphomas is rapidly
being elucidated and it is expected that mutation detection will in-
ﬂuence treatment decisions regarding targeted therapy.
• For now however, only demonstration of TP53 mutations and/or del
17p in CLL/SLL have a direct impact on therapy.
Research agenda
• Correlation of mutational status with response to targeted treatment
• Development of functional assays to predict treatment responses
more accurately.
• Reﬁnement of diagnostic criteria based on subgroups that arise from
large-scale sequencing eﬀorts.
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